MaxCyte, Inc. Amendments to Bylaws (7572H)
August 05 2021 - 11:05AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7572H
MaxCyte, Inc.
05 August 2021
Amendments to Bylaws
GAITHERSBURG, MD, August 5, 2021 - MaxCyte, Inc., (NASDAQ: MXCT)
(LSE: MXCT, MXCN) ("MaxCyte" or the "Company"), a leading provider
of cell-engineering platform technologies, announces that it has
filed amended and restated Bylaws (the "Bylaws") with the U.S.
Securities and Exchange Commission on Form 8-K.
In line with the Company's previous announcement on 29 July 2021
relating to the listing of the Company's common stock on Nasdaq,
certain rights have been incorporated into the Bylaws which the
Company believes stockholders would expect to see in a company
whose shares are admitted to trading on a U.S. listed exchange.
Copies of this document can found on the company's website, and
be downloaded via the following link:
https://investors.maxcyte.com/static-files/efd81a4a-09b7-4d8f-a773-d6c1693fa29a
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies to advance innovative cell-based research, development
and potential commercialisation of next-generation cell therapies.
The company's existing customer base ranges from large
biopharmaceutical companies -- including 20 of the top 25
pharmaceutical companies based on 2020 global revenue -- to
hundreds of biotechnology companies and academic translational
centers. MaxCyte has granted 13 strategic platform licences to
commercial cell therapy developers that allow for more than 75
clinical programmes. Founded in 1998, MaxCyte is headquartered in
Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith / Matthew O'Dowd +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams +44 (0)20 7710 7600
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Forward-Looking Statements
Certain statements made in this press release are
forward-looking statements including with respect to the admission
of the shares of common stock to trading on AIM. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including if the
shares of common stock are not admitted to trading on AIM or
admission is delayed or if there are adverse market or economic
conditions. The Company cautions security holders and prospective
security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this press release. The forward-looking
statements made in this press release relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSSFFIIEFSESA
(END) Dow Jones Newswires
August 05, 2021 11:05 ET (15:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024